References
- Rao V, Lyketsos CG. Psychiatric aspects of traumatic brain injury. Psychiatr Clin North Am. 2002;25(1):43–69. doi:https://doi.org/10.1016/s0193-953x(03)00052-2.
- Rao V, Lyketsos C. Neuropsychiatric sequelae of traumatic brain injury. Psychosomatics. 2000;41(2):95–103. doi:https://doi.org/10.1176/appi.psy.41.2.95.
- Dikmen SS, Bombardier CH, Machamer JE, Fann JR, Temkin NR. Natural history of depression in traumatic brain injury. Arch Phys Med Rehabil. 2004;85(9):1457–64. doi:https://doi.org/10.1016/j.apmr.2003.12.041.
- Lezak MD. Assessment of mild, moderate, and severe head injury. In: von Steinbüchel N, von Cramon DY, Pöppel E, editors. Neuropsychological rehabilitation. Berlin Heidelberg: Springer; 1992. p. 114–20.
- Salmond CH, Chatfield DA, Menon DK, Pickard JD, Sahakian BJ. Cognitive sequelae of head injury: involvement of basal forebrain and associated structures. Brain. 2005;128(Pt 1):189–200. doi:https://doi.org/10.1093/brain/awh352.
- Prigatano GP, Fordyce DJ, Zeiner HK, Roueche JR, Pepping M, Wood BC. Neuropsychological rehabilitation after closed head injury in young adults. J Neurol Neurosurg Psychiatry. 1984;47(5):505–13. doi:https://doi.org/10.1136/jnnp.47.5.505.
- Johansson B, Wentzel AP, Andréll P, Odenstedt J, Mannheimer C, Rönnbäck L. Evaluation of dosage, safety and effects of methylphenidate on post-traumatic brain injury symptoms with a focus on mental fatigue and pain. Brain Inj. 2014;28(3):304–10. doi:https://doi.org/10.3109/02699052.2013.865267.
- Giacino JT, Whyte J, Bagiella E, Kalmar K, Childs N, Khademi A, Eifert B, Long D, Katz DI, Cho S, et al. Placebo-controlled trial of amantadine for severe traumatic brain injury. N Engl J Med. 2012;366(9):819–26. doi:https://doi.org/10.1056/NEJMoa1102609.
- Jennett B, Snoek J, Bond MR, Brooks N. Disability after severe head injury: observations on the use of the glasgow outcome scale. J Neurol Neurosurg Psychiatry. 1981;44(4):285–93. doi:https://doi.org/10.1136/jnnp.44.4.285.
- Arciniegas D, Adler L, Topkoff J, Cawthra E, Filley CM, Reite M. Attention and memory dysfunction after traumatic brain injury: cholinergic mechanisms, sensory gating, and a hypothesis for further investigation. Brain Inj. 1999;13(1):1–13. doi:https://doi.org/10.1080/026990599121827.
- Murdoch I, Nicoll JAR, Graham DI, Dewar D. Nucleus basalis of Meynert pathology in the human brain after fatal head injury. J Neurotrauma. 2002;19(2):279–84. doi:https://doi.org/10.1089/08977150252807018.
- Murdoch I, Perry EK, Court JA, Graham DI, Dewar D. Cortical cholinergic dysfunction after human head injury. J Neurotrauma. 1998;15(5):295–305. doi:https://doi.org/10.1089/neu.1998.15.295.
- Everitt BJ, Robbins TW. Central cholinergic systems and cognition. Annu Rev Psychol. 1997;48(1):649–84. doi:https://doi.org/10.1146/annurev.psych.48.1.649.
- Rogers SL, Friedhoff LT. The efficacy and safety of donepezil in patients with Alzheimer’s disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial. The donepezil study group. Dement Basel Switz. 1996;7(6):293–303. doi:https://doi.org/10.1159/000106895.
- Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer’s disease. Donepezil study Group. Neurology. 1998;50(1):136–45. doi:https://doi.org/10.1212/wnl.50.1.136.
- Goldberg E, Gerstman LJ, Mattis S, Hughes JE, Bilder RM, Sirio CA. Effects of cholinergic treatment on posttraumatic anterograde amnesia. Arch Neurol. 1982;39(9):581. doi:https://doi.org/10.1001/archneur.1982.00510210051012.
- Diaz-Arrastia R, Kochanek PM, Bergold P, Kenney K, Marx CE, Grimes CJB, Loh LY, Adam LTCGE, Oskvig D, Curley KC, et al. Pharmacotherapy of traumatic brain injury: state of the science and the road forward: report of the department of defense neurotrauma pharmacology workgroup. J Neurotrauma. 2014;31(2):135–58. doi:https://doi.org/10.1089/neu.2013.3019.
- Bengtsson M, Godbolt A. Effects of acetylcholinesterase inhibitors on cognitive function in patients with chronic traumatic brain injury: a systematic review. J Rehabil Med. 2016;48(1):1–5. doi:https://doi.org/10.2340/16501977-2040.
- Ballesteros J, Güemes I, Ibarra N, Quemada JI. The effectiveness of donepezil for cognitive rehabilitation after traumatic brain injury: a systematic review. J Head Trauma Rehabil. 2008;23(3):171–80. doi:https://doi.org/10.1097/01.HTR.0000319935.99837.96.
- Poole NA, Agrawal N. Cholinomimetic agents and neurocognitive impairment following head injury: a systematic review. Brain Inj. 2008;22(7–8):519–34. doi:https://doi.org/10.1080/02699050802132495.
- Griffin SL, van Reekum R, Masanic C. A review of cholinergic agents in the treatment of neurobehavioral deficits following traumatic brain injury. J Neuropsychiatry Clin Neurosci. 2003;15(1):17–26. doi:https://doi.org/10.1176/jnp.15.1.17.
- Whitlock JA. Brain injury, cognitive impairment, and donepezil. J Head Trauma Rehabil. 1999;14(4):424–27. doi:https://doi.org/10.1097/00001199-199908000-00010.
- Walker W, Seel R, Gibellato M, Lew H, Cornis-Pop M, Jena T, Silver T. The effects of Donepezil on traumatic brain injury acute rehabilitation outcomes. Brain Inj. 2004;18(8):739–50. [Accessed 2020 June 24]. https://doi.org/10.1080/02699050310001646224.
- Noh MY, Koh SH, Kim Y, Kim HY, Cho GW, Kim SH. Neuroprotective effects of donepezil through inhibition of GSK-3 activity in amyloid-beta-induced neuronal cell death. J Neurochem. 2009;108(5):1116–25. doi:https://doi.org/10.1111/j.1471-4159.2008.05837.x.
- Campbell KA, Kennedy RE, Brunner RC, Hollis SD, Lumsden RA, Novack TA. The effect of donepezil on the cognitive ability early in the course of recovery from traumatic brain injury. Brain Inj. 2018;32(8):972–79. doi:https://doi.org/10.1080/02699052.2018.1468574.
- Raskind MA, Peskind ER, Wessel T, Yuan W. Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. Neurology. 2000;54(12):2261–68. doi:https://doi.org/10.1212/WNL.54.12.2261.
- Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Ding C. A 5-month, randomized, placebo-controlled trial of galantamine in AD. Neurology. 2000;54(12):2269–76. [Accessed 2021 June 22]. http://www.neurology.org/cgi/doi/https://doi.org/10.1212/WNL.54.12.2269.
- Bickel U, Thomsen T, Weber W, Fischer JP, Bachus R, Nitz M, Kewitz H. Pharmacokinetics of galanthamine in humans and corresponding cholinesterase inhibition. Clin Pharmacol Ther. 1991;50(4):420–28. doi:https://doi.org/10.1038/clpt.1991.159.
- Scott LJ, Goa KL. Galantamine: a review of its use in Alzheimer??s Disease. Drugs. 2000;60(5):1095–122. doi:https://doi.org/10.2165/00003495-200060050-00008.
- Thompson CA. FDA approves galantamine for Alzheimer’s disease. Am J Health Syst Pharm. 2001;58(8):649–649. doi:https://doi.org/10.1093/ajhp/58.8.649a.
- Wilcock GK, Lilienfeld S, Gaens E. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer’s disease: multicentre randomised controlled trial. BMJ. 2000;321(7274):1445–1445. [Accessed 2021 June 22]. https://www.bmj.com/lookup/doi/https://doi.org/10.1136/bmj.321.7274.1445.
- Spencer CM, Noble S. Rivastigmine: a review of its use in Alzheimer’s Disease. Drugs Aging. 1998;13(5):391–411. doi:https://doi.org/10.2165/00002512-199813050-00005.
- Kennedy JS, Polinsky RJ, Johnson B, Loosen P, Enz A, Laplanche R, Schmidt D, Mancione LC, Parris WCV, Ebert MH, et al. Preferential cerebrospinal fluid Acetylcholinesterase inhibition by rivastigmine in humans. J Clin Psychopharmacol. 1999;19(6):513–21. doi:https://doi.org/10.1097/00004714-199912000-00005.
- Jann MW. Pharmacology and clinical efficacy of cholinesterase inhibitors. Am J Health Syst Pharm. 1998;55(suppl_2):S22–S25. doi:https://doi.org/10.1093/ajhp/55.suppl_2.S22.
- Jann MW. Rivastigmine, a new-generation cholinesterase inhibitor for the treatment of Alzheimer’s disease. Pharmacotherapy. 2000;20(1):1–12. doi:https://doi.org/10.1592/phco.20.1.1.34664.
- Hossain M, Jhee SS, Shiovitz T, McDonald C, Sedek G, Pommier F, Cutler NR. Estimation of the absolute bioavailability of rivastigmine in patients with mild to moderate dementia of the Alzheimer???s Type. Clin Pharmacokinet. 2002;41(3):225–34. doi:https://doi.org/10.2165/00003088-200241030-00006.
- McKeith I, Del Ser T, Spano P, Emre M, Wesnes K, Anand R, Cicin-Sain A, Ferrara R, Spiegel R. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet Lond Engl. 2000;356(9247):2031–36. doi:https://doi.org/10.1016/S0140-6736(00)03399-7.
- Rosler M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, Dal-Bianco P, Stahelin HB, Hartman R, Gharabawi M, Bayer T, et al. Efficacy and safety of rivastigmine in patients with Alzheimer’s disease: international randomised controlled trial commentary: another piece of the Alzheimer’s jigsaw. BMJ. 1999;318(7184):633–40. [Accessed 2021 June 22]. https://doi.org/10.1136/bmj.318.7184.633.
- Forette F, Anand R, Gharabawi G. A phase II study in patients with Alzheimer’s disease to assess the preliminary efficacy and maximum tolerated dose of rivastigmine (ExelonR). Eur J Neurol. 1999;6(4):423–29. doi:https://doi.org/10.1046/j.1468-1331.1999.640423.x.
- Emre M, Aarsland D, Albanese A, Byrne EJ, Deuschl G, De Deyn PP, Durif F, Kulisevsky J, van Laar T, Lees A, et al. Rivastigmine for dementia associated with Parkinson’s disease. N Engl J Med. 2004;351(24):2509–18. doi:https://doi.org/10.1056/NEJMoa041470.
- Multicenter evaluation of memory remediation after TBI with donepezil - full text view - ClinicalTrials.gov; [Accessed June 24, 2020]. https://clinicaltrials.gov/ct2/show/NCT02255799.
- Zhang L, Plotkin RC, Wang G, Sandel ME, Lee S. Cholinergic augmentation with donepezil enhances recovery in short-term memory and sustained attention after traumatic brain injury. Arch Phys Med Rehabil. 2004;85(7):1050–55. doi:https://doi.org/10.1016/j.apmr.2003.10.014.
- Kim YW, Kim DY, Shin JC, Park CI, Lee JD. The changes of cortical metabolism associated with the clinical response to donepezil therapy in traumatic brain injury. Clin Neuropharmacol. 2009;32(2):63–68. doi:https://doi.org/10.1097/WNF.0b013e31816f1bc1.
- Silver JM, Koumaras B, Chen M, Mirski D, Potkin SG, Reyes P, Warden D, Harvey PD, Arciniegas D, Katz DI, et al. Effects of rivastigmine on cognitive function in patients with traumatic brain injury. Neurology. 2006;67(5):748–55. doi:https://doi.org/10.1212/01.wnl.0000234062.98062.e9.
- Silver JM, Koumaras B, Meng X, Potkin SG, Reyes PF, Harvey PD, Katz DI, Gunay I, Arciniegas DB. Long-term effects of rivastigmine capsules in patients with traumatic brain injury. Brain Inj. 2009;23(2):123–32. [Accessed 2021 June 23]. http://www.tandfonline.com/doi/full/https://doi.org/10.1080/02699050802649696.
- Tenovuo O, Alin J, Helenius H. A randomized controlled trial of rivastigmine for chronic sequels of traumatic brain injury—What it showed and taught? Brain Inj. 2009;23(6):548–58. doi:https://doi.org/10.1080/02699050902926275.
- McAllister TW, Zafonte R, Jain S, Flashman LA, George MS, Grant GA, He F, Lohr JB, Andaluz N, Summerall L, et al. Randomized Placebo-Controlled Trial Of Methylphenidate Or Galantamine For Persistent Emotional And Cognitive Symptoms Associated with PTSD and/or traumatic brain injury. Neuropsychopharmacology. 2016;41(5):1191–98. doi:https://doi.org/10.1038/npp.2015.282.
- Brawman-Mintzer O, Tang XC, Bizien M, Harvey, PD, Horner, MD, Arciniegas, DB, Raskind, M, Johnson-Greene, L, Martineau, RJ, McGarity, S, et al. Rivastigmine transdermal patch treatment for moderate to severe cognitive impairment in veterans with traumatic brain injury (RiVET study): a randomized clinical trial. J Neurotrauma. Published online 2021 March 8:neu.2020.7146. doi:https://doi.org/10.1089/neu.2020.7146.
- Tenovuo O. Central acetylcholinesterase inhibitors in the treatment of chronic traumatic brain injury—clinical experience in 111 patients. Prog Neuropsychopharmacol Biol Psychiatry. 2005;29(1):61–67. doi:https://doi.org/10.1016/j.pnpbp.2004.10.006.
- Östberg A, Virta J, Rinne JO, Oikonen V, Luoto P, Någren K, Arponen E, Tenovuo O. Brain cholinergic function and response to rivastigmine in patients with chronic sequels of traumatic brain injury: a PET study. J Head Trauma Rehabil. 2018;33(1):25–32. doi:https://doi.org/10.1097/HTR.0000000000000279.
- Naguy A. Donepezil monotherapy for neurocognitive deficits and psychobehavioral disinhibition in an adolescent posttraumatic brain injury. Am J Ther. 2018;25(5):e593–e595. doi:https://doi.org/10.1097/MJT.0000000000000609.
- Bennouna M, Greene VB, Defranoux L. Adjuvant galantamine to risperidone improves negative and cognitive symptoms in a patient presenting with schizophrenialike psychosis after traumatic brain injury. J Clin Psychopharmacol. 2005;25(5):505–07. doi:https://doi.org/10.1097/01.jcp.0000177851.31157.66.
- Al Owesie RM, Morton CS. Psychopharmacologic intervention after hemorrhagic basal ganglia damage. J Neurol Sci. 2012;322(1–2):77–78. doi:https://doi.org/10.1016/j.jns.2012.06.014.
- Bourgeois JA, Bahadur N, Minjares S. Donepezil for cognitive deficits following traumatic brain injury: a case report. J Neuropsychiatry Clin Neurosci. 2002;14(4):463–64. doi:https://doi.org/10.1176/jnp.14.4.463.
- Samuel GS, Ng YS. A case report on the use of an acetylcholinesterase inhibitor (donepezil) in traumatic brain injury. Med J Malaysia. 2013;68(4):376–78.
- Foster M, Spiegel DR. Use of donepezil in the treatment of cognitive impairments of moderate traumatic brain injury. J Neuropsychiatry Clin Neurosci. 2008;20(1):106. doi:https://doi.org/10.1176/jnp.2008.20.1.106.
- Johnson B, Lai Sey MS, Bhalerao S. Results of galantamine treatment in acute traumatic brain injury. Psychosomatics. 2007;48(2):177–78. doi:https://doi.org/10.1176/appi.psy.48.2.177.
- Sugden SG, Kile SJ, Farrimond DD, Hilty DM, Bourgeois JA. Pharmacological intervention for cognitive deficits and aggression in frontal lobe injury. NeuroRehabilitation. 2006;21(1):3–7. doi:https://doi.org/10.3233/NRE-2006-21102.
- Taverni GS, Steven WLJP. Donepezil mediated memory improvement in traumatic brain injury during post acute rehabilitation. Brain Inj. 1998;12(1):77–80. doi:https://doi.org/10.1080/026990598122881.
- Trovato M, Slomine B, Pidcock F, Christensen J. The efficacy of donepezil hydrochloride on memory functioning in three adolescents with severe traumatic brain injury. Brain Inj. 2006;20(3):339–43. doi:https://doi.org/10.1080/02699050500487811.
- Whelan FJ, Walker MS, Schultz SK. Donepezil in the treatment of cognitive dysfunction associated with traumatic brain injury. Ann Clin Psychiatry Off J Am Acad Clin Psychiatr. 2000;12(3):131–35. doi:https://doi.org/10.1023/a:1009008816928.
- Khateb A, Ammann J, Annoni JM, Diserens K. Cognition-enhancing effects of donepezil in traumatic brain injury. Eur Neurol. 2005;54(1):39–45. doi:https://doi.org/10.1159/000087718.
- Kaye NS, Townsend III JB, Ivins R. An open-label trial of donepezil (Aricept) in the treatment of persons with mild traumatic brain injury. J Neuropsychiatry Clin Neurosci. 2003;15(3):383–84. doi:https://doi.org/10.1176/jnp.15.3.383.
- Masanic CA, Bayley MT, vanReekum R, Simard M. Open-label study of donepezil in traumatic brain injury. Arch Phys Med Rehabil. 2001;82(7):896–901. doi:https://doi.org/10.1053/apmr.2001.23833.
- Morey CE, Cilo M, Berry J, Cusick C. The effect of Aricept® in persons with persistent memory disorder following traumatic brain injury: a pilot study. Brain Inj. 2003;17(9):809–15. doi:https://doi.org/10.1080/0269905031000088586.
- Dávila G, Moyano MP, Edelkraut L, Moreno-Campos L, Berthier ML, Torres-Prioris MJ, López-Barroso D. Pharmacotherapy of traumatic childhood aphasia: beneficial effects of donepezil alone and combined with intensive naming therapy. Front Pharmacol. 2020;11:1144.
- Vogel SM, Mican LM, Smith TL. Donepezil-induced QTc prolongation: a case report. Ment Health Clin. 2019;9(3):128–32. doi:https://doi.org/10.9740/mhc.2019.05.128.
- Kang SH, Kim DK. Drug induced parkinsonism caused by the concurrent use of donepezil and risperidone in a patient with traumatic brain injuries. Ann Rehabil Med. 2013;37(1):147. doi:https://doi.org/10.5535/arm.2013.37.1.147.
- Kumlien E, Lundberg PO. Seizure risk associated with neuroactive drugs: data from the WHO adverse drug reactions database. Seizure. 2010;19(2):69–73. doi:https://doi.org/10.1016/j.seizure.2009.11.005.
- Griffith HR, Martin R, Andrews S, LeBron Paige A, Ware J, Faught E, Welty T. The safety and tolerability of galantamine in patients with epilepsy and memory difficulties. Epilepsy Behav. 2008;13(2):376–80. doi:https://doi.org/10.1016/j.yebeh.2008.05.006.
- Fisher RS, Bortz JJ, Blum DE, Duncan B, Burke H. A pilot study of donepezil for memory problems in epilepsy. Epilepsy Behav. 2001;2(4):330–34. doi:https://doi.org/10.1006/ebeh.2001.0221.
- Englander J, Cifu DX, Diaz-Arrastia R. Seizures and traumatic brain injury. Arch Phys Med Rehabil. 2014;95(6):1223–24. doi:https://doi.org/10.1016/j.apmr.2013.06.002.
- Englander J, Bushnik T, Duong TT, Cifu DX, Zafonte R, Wright J, Hughes R, Bergman W. Analyzing risk factors for late posttraumatic seizures: a prospective, multicenter investigation. Arch Phys Med Rehabil. 2003;84(3):365–73. doi:https://doi.org/10.1053/apmr.2003.50022.
- Reddy CC, Collins M, Lovell M, Kontos AP. Efficacy of amantadine treatment on symptoms and neurocognitive performance among adolescents following sports-related concussion. J Head Trauma Rehabil. 2013;28(4):260–65. doi:https://doi.org/10.1097/HTR.0b013e318257fbc6.
- Kolli V, Dickson J, Amani M, Tan J. Posttraumatic stress disorder exacerbation with cholinesterase inhibitor in a patient with dementia. Innov Clin Neurosci. 2013;10(9–10):11–12.
- McLay RN, Webb-Murphy J, Hammer P, Volkert S, Klam W. Post-traumatic stress disorder symptom severity in service members returning from Iraq and Afghanistan with different types of injuries. CNS Spectr. 2012;17(1):11–15. doi:https://doi.org/10.1017/S1092852912000016.
- Thornton SL, Pchelnikova JL, Cantrell FL. Characteristics of pediatric exposures to antidementia drugs reported to a poison control system. J Pediatr. 2016;172:147–50. doi:https://doi.org/10.1016/j.jpeds.2016.01.056.
- Alavi A. Functional and anatomic studies of head injury. J Neuropsychiatry Clin Neurosci. 1989;1(1):S45–50.
- Newberg AB, Alavi A. Neuroimaging in patients with head injury. Semin Nucl Med. 2003;33(2):136–47. doi:https://doi.org/10.1053/snuc.2003.127299.
- Ma HM, Zafonte RD. Amantadine and memantine: a comprehensive review for acquired brain injury. Brain Inj. 2020;34(3):299–315. doi:https://doi.org/10.1080/02699052.2020.1723697.